Phio Pharmaceuticals (PHIO) Competitors $2.73 +0.03 (+1.11%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$2.73 0.00 (0.00%) As of 04/17/2025 06:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PHIO vs. ALXO, HOWL, BRNS, CVKD, FGEN, IRD, GDTC, DARE, GBIO, and PLURShould you be buying Phio Pharmaceuticals stock or one of its competitors? The main competitors of Phio Pharmaceuticals include ALX Oncology (ALXO), Werewolf Therapeutics (HOWL), Barinthus Biotherapeutics (BRNS), Cadrenal Therapeutics (CVKD), FibroGen (FGEN), Opus Genetics (IRD), CytoMed Therapeutics (GDTC), Daré Bioscience (DARE), Generation Bio (GBIO), and Pluri (PLUR). These companies are all part of the "pharmaceutical products" industry. Phio Pharmaceuticals vs. ALX Oncology Werewolf Therapeutics Barinthus Biotherapeutics Cadrenal Therapeutics FibroGen Opus Genetics CytoMed Therapeutics Daré Bioscience Generation Bio Pluri ALX Oncology (NASDAQ:ALXO) and Phio Pharmaceuticals (NASDAQ:PHIO) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, community ranking, risk, dividends, earnings, media sentiment, analyst recommendations, institutional ownership and profitability. Is ALXO or PHIO more profitable? ALX Oncology's return on equity of -93.02% beat Phio Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets ALX OncologyN/A -93.02% -70.67% Phio Pharmaceuticals N/A -134.57%-108.39% Do analysts rate ALXO or PHIO? ALX Oncology presently has a consensus target price of $4.14, indicating a potential upside of 652.73%. Phio Pharmaceuticals has a consensus target price of $4.00, indicating a potential upside of 46.52%. Given ALX Oncology's higher probable upside, equities analysts plainly believe ALX Oncology is more favorable than Phio Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ALX Oncology 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.71Phio Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to ALXO or PHIO? In the previous week, Phio Pharmaceuticals had 3 more articles in the media than ALX Oncology. MarketBeat recorded 3 mentions for Phio Pharmaceuticals and 0 mentions for ALX Oncology. Phio Pharmaceuticals' average media sentiment score of 0.24 beat ALX Oncology's score of 0.00 indicating that Phio Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment ALX Oncology Neutral Phio Pharmaceuticals Neutral Which has better valuation & earnings, ALXO or PHIO? Phio Pharmaceuticals is trading at a lower price-to-earnings ratio than ALX Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioALX OncologyN/AN/A-$160.80M-$2.60-0.21Phio PharmaceuticalsN/AN/A-$10.83M-$10.92-0.25 Does the MarketBeat Community prefer ALXO or PHIO? ALX Oncology received 17 more outperform votes than Phio Pharmaceuticals when rated by MarketBeat users. Likewise, 64.71% of users gave ALX Oncology an outperform vote while only 64.41% of users gave Phio Pharmaceuticals an outperform vote. CompanyUnderperformOutperformALX OncologyOutperform Votes5564.71% Underperform Votes3035.29% Phio PharmaceuticalsOutperform Votes3864.41% Underperform Votes2135.59% Which has more risk & volatility, ALXO or PHIO? ALX Oncology has a beta of 1.2, meaning that its stock price is 20% more volatile than the S&P 500. Comparatively, Phio Pharmaceuticals has a beta of 1.09, meaning that its stock price is 9% more volatile than the S&P 500. Do insiders and institutionals hold more shares of ALXO or PHIO? 98.0% of ALX Oncology shares are held by institutional investors. Comparatively, 57.3% of Phio Pharmaceuticals shares are held by institutional investors. 33.4% of ALX Oncology shares are held by company insiders. Comparatively, 0.6% of Phio Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. SummaryALX Oncology beats Phio Pharmaceuticals on 11 of the 15 factors compared between the two stocks. Get Phio Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PHIO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PHIO vs. The Competition Export to ExcelMetricPhio PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$13.04M$6.45B$5.30B$7.34BDividend YieldN/A3.23%5.12%4.30%P/E Ratio-0.256.8921.8017.78Price / SalesN/A231.03379.9697.74Price / CashN/A65.6738.2634.64Price / Book0.155.916.443.97Net Income-$10.83M$142.72M$3.21B$247.65M7 Day Performance56.90%4.38%2.85%1.80%1 Month Performance96.40%-12.76%-8.64%-6.98%1 Year Performance-52.23%-9.69%11.38%1.34% Phio Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PHIOPhio Pharmaceuticals2.5896 of 5 stars$2.73+1.1%$4.00+46.5%-52.7%$13.04MN/A-0.2510ALXOALX Oncology3.0355 of 5 stars$0.54+3.8%$4.14+673.4%-96.6%$28.58MN/A-0.1840HOWLWerewolf Therapeutics2.8709 of 5 stars$0.63-9.8%$9.00+1,328.6%-84.3%$28.24M$1.89M-0.4140News CoverageGap UpBRNSBarinthus Biotherapeutics2.8684 of 5 stars$0.69+1.8%$5.17+644.5%-71.9%$28.00M$14.97M-0.47107Short Interest ↓Positive NewsGap UpCVKDCadrenal Therapeutics1.9993 of 5 stars$14.68-9.2%$32.00+118.0%N/A$27.60MN/A-2.204News CoverageGap DownFGENFibroGen4.1352 of 5 stars$0.27-2.5%$10.00+3,561.7%-77.5%$27.56M$29.62M-0.22570Analyst ForecastGap DownIRDOpus Genetics1.848 of 5 stars$0.85-4.5%$8.00+845.6%N/A$27.11M$10.99M-0.7814GDTCCytoMed Therapeutics2.0615 of 5 stars$2.35-1.5%$5.00+113.2%+18.8%$25.65MN/A0.00N/AGap DownDAREDaré Bioscience1.9408 of 5 stars$2.88-0.3%$24.00+733.3%-14.5%$25.49M$9,784.00-4.8830Short Interest ↓News CoverageGBIOGeneration Bio2.7854 of 5 stars$0.38+0.8%$7.33+1,853.5%-86.9%$25.16M$19.89M-0.17150PLURPluri1.0902 of 5 stars$3.58-2.2%N/A-24.1%$25.05M$678,000.00-0.64150Short Interest ↓News Coverage Related Companies and Tools Related Companies ALXO Competitors HOWL Competitors BRNS Competitors CVKD Competitors FGEN Competitors IRD Competitors GDTC Competitors DARE Competitors GBIO Competitors PLUR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PHIO) was last updated on 4/18/2025 by MarketBeat.com Staff From Our PartnersClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | Sponsored100-year-old investment secret predicts what?!A 100-year-old indicator has quietly predicted nearly every major market meltdown — including the Dot-Com Bust...Weiss Ratings | SponsoredThe first casualty of the 2025 trade warThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredTrump 2028 could be a “bonanza” for investorsAs you may have heard, Donald Trump is planning to run for a THIRD term in 2028. Recently he told NBC news ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Phio Pharmaceuticals Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Phio Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PHIO Stock Free PHIO Stock Alerts